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Abstract
Purpose Writing an Advance Directive (AD) is often seen as a part of Advance Care Planning (ACP). ADs may include specific
preferences regarding future care and treatment and information that provides a context for healthcare professionals and relatives
in case they have to make decisions for the patient. The aim of this study was to get insight into the content of ADs as completed
by patients with advanced cancer who participated in ACP conversations.
Methods A mixed methods study involving content analysis and descriptive statistics was used to describe the content of
completed My Preferences forms, an AD used in the intervention arm of the ACTION trial, testing the effectiveness of the
ACTION Respecting Choices ACP intervention.
Results In total, 33% of 442 patients who received the ACTION RC ACP intervention completed a My Preferences form.
Document completion varied per country: 10.4% (United Kingdom), 20.6% (Denmark), 29.2% (Belgium), 41.7% (the
Netherlands), 61.3% (Italy) and 63.9% (Slovenia). Content analysis showed that ‘maintaining normal life’ and ‘experiencing
meaningful relationships’ were important for patients to live well. Fears and worries mainly concerned disease progression, pain
or becoming dependent. Patients hoped for prolongation of life and to be looked after by healthcare professionals. Most patients
preferred to be resuscitated and 44% of the patients expressed maximizing comfort as their goal of future care. Most patients
preferred ‘home’ as final place of care.
Electronic supplementary material The online version of this article
(https://doi.org/10.1007/s00520-019-04956-1) contains supplementary
material, which is available to authorized users.
* Marieke Zwakman
J.J.M.vanDelden@umcutrecht.nl
J. J. M. van Delden
Delden@umcutrecht.nl
G. Caswell
Glenys.caswell@nottingham.ac.uk
L. Deliens
Luc.Deliens@vub.be
F. Ingravallo
francesca.ingravallo@unibo.it
L. J. Jabbarian
l.jabbarian@erasmusmc.nl
A. T. Johnsen
Anna.Thit.Johnsen@regionh.dk
I. J. Korfage
i.korfage@erasmusmc.nl
A. Mimić
Alenka.Mimic@klinika-golnik.si
C. Møller Arnfeldt
caroline.moeller.arnfeldt@regionh.dk
N. J. Preston
n.j.preston@lancaster.ac.uk
M. C. Kars
m.c.kars@umcutrecht.nl
Extended author information available on the last page of the article
Supportive Care in Cancer (2020) 28:1513–1522
https://doi.org/10.1007/s00520-019-04956-1
Conclusions My Preferences forms provide some insights into patients’ perspectives and preferences. However, understanding
the reasoning behind preferences requires conversations with patients.
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Introduction
An Advance Directive (AD) provides a framework for
patients to document thoughts regarding future medical
care and treatment, to ensure that their wishes and pref-
erences can be followed if they become unable to make
their own decisions [1]. Although ADs can be helpful in
maintaining the quality of a patient’s end of life [2, 3],
the majority of people do not have an AD, mainly due
to a lack of knowledge of ADs or because an AD is
considered unnecessary now [4, 5]. Consequently, the
use of ADs in clinical practice remains low [4–10].
Advance Care Planning (ACP) conversations can be ef-
fective to increase the rate of completed ADs [11–13].
Therefore, the completion of ADs is no longer seen as
self-contained, but rather as a component of ACP. This
perspective is reflected in recently developed definitions
of ACP that include the opportunity to document wishes
for future care and treatment as part of the ACP process
[14, 15].
Currently, most ADs concern do-not-resuscitate orders,
or a durable power of attorney for healthcare, and they
often involve expressions of concrete treatment preferences
[16–18]. However, if ADs are part of the ACP process, it
may be helpful if they also include information on patients’
values, beliefs and more general wishes. This provides a
context for understanding the patient whenever healthcare
professionals and relatives are to make decisions on behalf
of patients who are not able to speak for themselves. To our
knowledge, there is only one study that has investigated the
content of ADs covering a broader range of topics [19].
This study showed that patients with haematological malig-
nancies described aspects related to medical treatments or
actions, effective pain treatment and personal messages for
their family in their ADs. What patients describe in a more
comprehensive AD in the context of a guided ACP conver-
sation has not yet been investigated. Consequently, we do
not know whether patients provide in-depth information on
their preferences in their ADs after having participated in a
guided ACP conversation. An analysis of ADs, made dur-
ing or following an ACP conversation, may provide insight
into the various factors that are important to seriously ill
patients.
The aim of this study was to get insight into the content of
ADs completed by patients with advanced cancer who partic-
ipated in a structured ACP conversation.
Methods
Research design
This study represents a sub-study of the ACTION trial, a
phase III multicentre cluster randomised controlled trial
that evaluates the ACTION Respecting Choices (RC)
ACP intervention in patients with advanced cancer
(Trial Number: ISRCTN63110516) [20]. Twenty-three
hospitals in six European countries—Belgium (BE),
Denmark (DK), Italy (IT), the Netherlands (NL),
Slovenia (SI) and the United Kingdom (UK)—were
randomised in the intervention arm (n = 12) (ACTION
RC ACP intervention) or control arm (care as usual)
(n = 11) [20]. The ACTION RC ACP intervention in-
volved one or two scripted conversations between an
ACTION RC ACP trained facilitator, the patient and, if
the patient wishes, a person nominated as their personal
representative (PR). The facilitators assisted patients dur-
ing these conversations in exploring their understanding
of their illness, reflecting on their goals and values and to
consider their future preferences (Supplementary file 1).
Additionally, facilitators encouraged patients to document
their goals and preferences for future medical treatment
and care in a so-called My Preferences Form (MPF)
(Supplementary file 2 and 3). The MPF was developed
for the ACTION trial and can be used—depending on
local regulations—as an AD. This comprehensive form
consisted of free text sections and tick box sections, re-
quiring qualitative and quantitative methods of analysis,
respectively. Therefore, a mixed method design was used
in which qualitative and quantitative strategies were pur-
sued in parallel [21].
Population
Patients with advanced lung cancer (small cell—extensive
disease/stage III or IV and non-small cell—stage III or IV)
or colorectal cancer (stage IV or metachronous metastases)
were invited by their treating healthcare professional to par-
ticipate in the ACTION trial between May 2015 and
December 2017. Patients were eligible to participate when
they were ≥ 18 years and had a WHO performance status of
≤ 3. Patients were excluded when they had less than 3-month
anticipated life expectancy or were unable to complete the
questionnaire in country’s language. For this sub-study, we
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included all patients participating in the intervention arm of
the ACTION trial who completed and returned a MPF as part
of this intervention.
Data collection
Data consisted of returned and completed MPFs. Data collec-
tion continued until 1 January 2019, 1 year after inclusion for
the ACTION trial had finished.
The MPF includes information about the patient’s PR, ex-
ploratory sections regarding ‘Living well’ (section A1),
‘Worries and fears’ (section A2), ‘Beliefs’ (section A3) and
‘Hopes’ (section B), and preferences sections concerning
Cardio-Pulmonary Resuscitation (CPR) (section C), goals of
future care (section D), final place of care (section E) and other
preferences (section F). MPFs where at least one of the six
sections of the form was filled in were included for analysis.
Background data (demographic characteristics and medical
conditions) were retrieved from the patients’medical files and
the facilitators’ report of the ACP conversation.
Data analysis
The ACTION research team of each country collected and
anonymised the MPFs.
The indicated preferences written in the tick boxes (sec-
tions C, D and E) were extracted and converted into an
Excel document. This data was analysed by quantitative de-
scriptive analyses using the Statistical Package for the Social
Sciences (SPSS version V21.0).
To facilitate qualitative analysis, the free text sections (sec-
tions A, B and F) were translated into English by the local
ACTION researchers of DK, IT and SI. Subsequently, the
content of all forms was imported into an Excel document.
This data was analysed using content analysis, a qualitative
method to analyse text data [22]. We started with (re) reading
the answers of the open sections to become familiar with the
data. Subsequently, two authors both skilled in conducting
qualitative research (MZ, MK) independently started with
open coding of the first three MPFs of each country (15% of
included MPFs). During several meetings, MZ and MK
discussed the initial codes per section of the MPF, working
towards intersubjective agreement. Related codes were then
clustered into categories (Supplementary file 4. Code tree).
MZ continued the process of coding and categorizing. MK
checked coding and the interpretation of the data. Saturation
was achieved, meaning that the analysis of the last included
MPFs did not uncover ideas that could not be assigned to
already existing categories [23]. The content analysis was
supported by NVivo 11.
One researcher of each local team checked whether the
reported outcomes were in line with the content of the MPFs
of their country. No significant adjustments to the categories
were made. Finally, relevant quotes were extracted from the
MPFs to fully convey the essence of the categories.
Ethical considerations
Ethical approval was obtained from the institutional review
board (IRB) of the coordinating centre (‘Medische Ethische
Toetsings Commissie (METC) Erasmus MC’), as well as
IRBs in all participating countries (NL 50012.078.14).
Informed consent was obtained from all individual partici-
pants in the study.
Results
Of the 442 patients who participated in the intervention arm of
the ACTION trial, 147 had returned the MPF by 1 January
2019. Document completion varied per country: 10.4% (UK),
20.6% (DK), 29.2% (BE), 41.7% (NL), 61.3% (IT) and 63.9%
(SI). Of the 147 MPFs, 125 forms were included for analysis
(Fig. 1). In total, 22 MPFs were excluded, mainly due to
limited resources for translation (n = 21). One patient refused
consent.
Respondents were on average 66.9 years of age, most of
them were male (61.2%) and 53.6% of the patients suffered
from lung cancer (Table 1). Many patients (n = 96) completed
the MPF during the ACTION RC ACP conversation. Most
patients completed at least four of the six sections (n = 114),
including 22 patients who completed all sections.
Below, each section of the MPF will be presented separate-
ly in the same order these sections appear in the MPF and the
percentage of patients who completed each section is
provided.
Personal representative (90%)
Of the 125 patients, 113 patients (90%) had chosen someone
tomake decisions on their behalf if they would become unable
to make decisions themselves.
Exploratory sections
Section A1 (free text): activities or experiences that are
important for me to live well (94%)
‘Maintaining normal life’, ‘undertaking activities’, ‘being in-
dependent’ and ‘experiencing meaningful relationships’ were
categories that appeared to be essential to live well for many
patients from all participating countries.
Patients often described in their MPF ‘maintaining normal
life’, for example: ‘To live a normal life, to maintain the ev-
eryday life’ (DK). It appeared that maintaining normal life
enabled some patients to enjoy life.
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The variety of described activities was captured
in the category ‘undertaking activities’. Daily activ-
ities such as walking, gardening and engaging in
hobbies were mentioned as well as special activi-
ties, such as going on holidays or activities with
beloved persons. ‘A day at the sea with my loved
ones’ (IT)
‘Being independent’ was described by patients in
different ways. Some patients used the word ‘inde-
pendent’ as such, others described for example being
able to communicate, being physically independent
and remaining mentally competent. ‘To be able to
take care of myself ’ (DK), ‘When I can do things
autonomously’ (IT) and ‘Being able to think clearly’
(SI).
‘Experiencing meaningful relationships’ was by
some patients described as having a ‘family life’
(DK) or ‘friendship’ (NL). Other patients elaborated
on their relationships, describing visits to family and
friends or engaging in activities with them, in partic-
ular with children and grandchildren. Some patients
described the importance of their life having mean-
ing, writing down for whom and how they wanted to
be of meaning. For instance, by contributing to their
organization as an employee or helping their children
by taking care of grandchildren.
Some patients, from NL, IT and the UK specifically, de-
scribed being free from pain in this section, mainly as a pre-
condition of living well.
Section A2 (free text): I have the following fears or worries
(74%)
Patients from all participating countries feared the conse-
quences of disease progression. Some patients expressed this
in a general way, ‘Fears and worries about the complications
of the illness’ (IT), while others were more concrete in their
worries and fears regarding disease progression. For example:
having less energy, physical decline, hopelessness suffering
and frightening experiences (e.g. ‘to be in pain’ [SI]).
Several patients described their fear of becoming dependent
or being in a vegetative state. As one patient expressed: ‘My
greatest fear is being trapped in an unresponsive body’ (UK).
Patients also struggled with unpredictability, worrying
about the outcomes of their treatment and howmuch time they
had left. ‘Naturally, I am worried about whether the treatment
will work on me’ (DK).
Becoming unable to maintain their normal life was a fear
expressed by a few patients as well as the worry or fear of
being taken to a final place of care they disliked.
Several patients from IT, NL and the UK worried about
being or becoming a burden or causing distress to their
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Fig. 1 Inclusion my preferences forms for analysis
relatives. Some patients worried about how their loved ones
would recover after they had passed away. For example, one
patient mentioned being married for 50 years and was worried
about his spouse.
Table 1 Background
characteristics of patients who
completed a MPF
N (%)
N patients 125 (100%)
Male 77 (61.6%)
Age Mean 66.9 (range 40–86)
Marital status
Married/civil partnership 81 (64.8%)
Unmarried 11 (8.8%)
Divorced/separated 16 (12.8%)
Widowed 15 (12%)
Living with a spouse/partner 86 (68.8%)
Living in a private household 118 (94.4%)
Children, yes 114 (91.2%)
Number of children living at home Mean 2 (range 1–3)
Total number of years of education Mean 12.9 (Range 5–26)
Being religious 52 (41.6%)
Catholic 30 (24%)
Protestant 5 (4%)
Church of England 5 (4%)
Member of a minority ethnic group in
your country
1 (0.8%)
Type of cancer
Small cell—extensive disease lung cancer 18 (14.4%)
Non-small cell lung cancer 49 (39.2%)
Colon cancer 42 (33.6%)
Rectal cancer 14 (11.2%)
Stage of cancer
Stage III, lung cancer 16 (12.8%)
Stage IV, lung cancer 51 (40.8%)
Colorectal cancer stage IV 44 (35.2%)
Colorectal cancer—metachronous metastases 11 (8.8%)
WHOa
0 40 (32%)
1 66 (52.8%
2 14 (11.2%)
3 2 (1.6%)
Current treatmentb
Chemotherapy 83 (66.4%)
Radiation therapy 18 (14.4%)
Immunotherapy 4 (3.2%)
Targeted therapy 12 (9.6%)
Data are means ± range or n (%) of total number of patients of whom information was available, this could be
different from the total n of 125
aWorld Health Organisation performance status scale (0—you are fully active andmore or less as you were before
your illness; 1—you cannot carry out heavy physical work, but can do anything else; 2—you are up and about
more than half the day and can look after yourself, but are not well enough to work; 3—you are in bed or sitting in
a chair for more than half the day and you need some help in looking after yourself; 4—you are in bed or a chair all
the time and need a lot of looking after)
b Some patients received more than one treatment at the same time
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Several patients wrote that they had no worries or not yet.
Others mentioned they actively avoided thinking about
worries and described living 1 day at the time or trying not
to think about worries and fears: ‘Of course I have fears and
worries, but I will not let my life be influenced by it. ‘It goes
the way it comes’ (NL).
Section A3 (free text): I have the following cultural, religious
or spiritual beliefs (55%)
Religion was described by most patients. Fifteen patients
specified their religion (e.g. Church of England, Catholic or
Christian). The same number of patients elaborated on the role
their religion played in their lives regarding their disease or
described preferences based on their religion. For example, ‘I
have no fear of dying, I know He is waiting for me’ (NL) or
‘Church of England. I would want to see the vicar if I was very
poorly’ (UK).
Regarding personal beliefs, a few patients described living
day-by-day, not giving up and being positive. One patient
described: ‘I believe in faith, that the course of life and expe-
riences are predestined’ (SI). Some patients addressed their
belief in science and the health system. Not having any beliefs
that affected their wishes was also described by a number of
patients.
Section B (free text): my hopes for my current medical plan
of care include (96%)
The majority of patients hoped for prolongation of life.
Several patients expressed this as hope for a cure, remaining
stable or the hope that their tumour would shrink. Other pa-
tients described prolongation of life in terms of being able to
reach a special moment. ‘I hope to await my daughter’s grad-
uation’ (BE). A few patients wanted to prolong their lives in
the hope that science would make progress on treatment that
improved their chance for survival.
Hope to diminish the burden of the disease was also de-
scribed and included being free from suffering as well as
symptom relief. Patients mentioned in particular the hope of
being free from pain.
Patients from all participating countries described their
hope to remain independent and expressed the hope that they
would remain able to take care of themselves.
Another hope expressed by patients was being looked after
by healthcare professionals. This was specified as the hope for
frequent appointments and good collaboration with the
healthcare professional, which included receiving clear and
honest information.
Some patients shared their goals of care in the case of deteri-
oration (NL, SI, UK). For example, ‘To a certain limit (treatment)
as long as tolerant and humane tome’ (NL). Others hoped to stay
at home as long as possible (BE, NL, UK) or to die with dignity
(BE, IT, UK): ‘When it comes to the end, I want to go in peace
and not to keep me hanging on.’ (UK).
Described hopes also included maintaining a normal life and
enjoying life: ‘Hope chemo will maintain my current quality of
life’ (UK). Some patients fromNL, ITand SI described their state
of mind in the section of hope. These patients wanted to stay
positive, were willing to fight or trusted their healthcare profes-
sional. Only one patient described not having any hopes because
of the advanced stage of the disease.
Preferences sections
Section C (tick box): my preferences regarding resuscitation
(96%)
Two thirds of the patients (n = 78) indicated their preference to
receive CPR if their physician considered it medically appro-
priate in their actual situation (Table 2). This option was cho-
sen most often in ITand DK (respectively, 89.5% and 76.9%).
Eight patients explained their choice by referring to the cir-
cumstances in which they did or did not want CPR. ‘If after
CPR I will return in a condition I am right now, I would
choose CPR. Otherwise not’ (SI).
Section D (tick box): my goals of future care (92%)
Preferences regarding goals of future care were almost equally
divided between ‘Comfort-Focused Care’ and ‘Selective
Treatment plus Comfort-Focused Care’ (Table 2). In NL and
BE, the majority of the patients preferred ‘Comfort-Focused
Care’. In other countries, the majority of the patients chose
‘Selective Treatment plus Comfort-Focused Care’, where the
primary goal is treating a complication. All Italian respon-
dents, except for two, chose the latter option.
A few patients precisely articulated what they meant by
their preferences. For example: ‘Would like to have for exam-
ple IVantibiotics, if it seems to have an effect and it is only for
a short period of time. Do not wish to be treated for infections
if the illness is much progressed and it is futile’ (DK).
Section E (tick box): my preferences regarding final place
of care (96%)
In all six countries, the vast majority of patients reported a
preferred final place of care (84%), most often ‘home’ (n =
75) (Table 2). Others preferred a hospice (n = 20) or hospital
(n = 10). Patients who added specific information (n = 24)
mainly specified personal aspects of quality ‘[living] at home
with family’ (IT), ‘[living] as long as possible and in a good
condition’ (BE) or ‘with a view to my garden’ (NL). A few
patients added what they did not want. ‘Hospice/hospital. Not
home’ (UK).
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Section F (free text): my other preferences that I consider
important to be known by those who care for me (41%)
Most patients used this section to add explanations following
the information provided in one of the previous sections of the
MPF. To illustrate: ‘If causing distress to family or if unable to
be treated at home, I would like my personal representative to
decide if a nursing home, hospital or hospice is the best alter-
native’ (UK).
A few patients wrote down preferences regarding their
wish for alternative treatment, or to prevent futile treat-
ment. A wish for euthanasia in the case of unbearable
suffering was reported by a few patients from NL and
BE.
Preferences regarding the stage of deterioration and dying
were alsomentioned, including wishes about visitors and fam-
ily (‘I wish that not too many people will visit at one time’
[DK]) and being free from pain.
After-death arrangements were also described by several
patients. Some patients shared their preferences regarding
their funeral (e.g. cremation and pictures on the coffin) or
organ donation.
Discussion
We found that one third of patients participating in an ACP
intervention completed an AD. The degree of completion var-
ied substantially between countries. Analysis of ADs showed
that the topics described by patients in the exploratory sections
mainly concerned maintaining a normal life, hope for
prolonging life and experiencing meaningful relationships.
Also, the fear of suffering from disease progression and be-
coming dependent was often described. Most patients chose a
PR and preferred ‘home’ as their final place of care.
Preferences regarding CPR and goals of future care varied
between patients and countries.
In the exploratory sections, many patients described their
values, wishes and hopes, as well as their fears or worries in a
rather concrete way. Similar to a study by Trarieux-Signol
et al. (2018) [19], who predominantly analysed blank sheet
ADs, we found that preventing functional and mental depen-
dency, effective symptom treatment and after-death arrange-
ments were considered important [19]. However, it seemed
that patients in our study providedmore information regarding
worries, fears and hopes. To illustrate, patients not only
Table 2 Indicated preferences
BE DK IT NL SI UK Total
(n = 21) (n = 13) (n = 19) (n = 35) (n = 25) (n = 12) (n = 125)
Cardio pulmonary resuscitation (CPR)
(section C)
I wish to have CPR attempted if my
physicianconsiders it medically
appropriate in my actual situation.
11 (52.4%) 10 (76.9%) 17 (89.5%) 20 (57.1%) 13 (52%) 7 (58.3%) 78 (62.4%)
I do not wish CPR attempted if my
heart or breathing stops.
9 (42.9%) 3 (23.1%) 2 (10.5%) 14 (40%) 7 (28%) 5 (41.7%) 40 (32%)
Added sentencesa 1 4 0 1 2 0 8
Left open 1 (4.8%) 0 0 0 4 (16%) 0 5 (4%)
Goals of care (section D)
Selective treatment plus comfort-
focused care
3 (14.3%) 6 (46.2%) 17 (89.5%) 12 (36.3%) 12 (48%) 8 (66.7%) 58 (46.4%)
Comfort-focused care 13 (61.9%) 5 (38.5%) 2 (10.5%) 22 (63%) 9 (36%) 3 (25%) 54 (43.9%)
Added sentencesa 1 3 0 8 4 2 18
Left open 5 (23.8%) 2 (15.4%) 0 0 3 (12%) 0 10 (8%)
Final place of care (section E)
I have a preferred final place of care 16 (76.2%) 11 (84.6%) 14 (73.7%) 28 (80%) 25 (100%) 11 (91.6%) 105 (84%)
This place isb:
Home 10 6 7 24 20 8 75
Hospice 3 6 3 6 0 2 20
Hospital 5 1 2 0 0 2 10
Other 0 2 3 0 5 0 9
I do not have a preferred final
place of care.
4 (19.0%) 2 (15.4% 3 (15.8%) 6 (17.1%) 0 0 15 (12.2%)
Left open 1 (4.8%) 0 2 (14.3%) 1 (2.9%) 0 1 (8.3%) 5 (4%)
a Either added sentences to the choice made or only described information without making a choice
bPatients could write more than one preferred final place of care
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formulated their hope to prolong life, but also their hope that
science would make progress to improve their chances for
prolonging their lives. It is likely that patients provided more
information because they were asked specifically about this
during the ACP conversation. Studies investigating hope in
palliative care confirm this variety in objectives, meanings and
functions of hope [24–26].
A completed AD with such broad information might
provide healthcare professionals and relatives with a bet-
ter insight into the patients’ perspectives and might im-
prove the guidance of the professionals throughout the
end of life process when applying the AD. However, pre-
vious studies described the importance of ADs being as
precise as possible and that ADs should include relevant
information for healthcare professionals to make decisions
[19, 27, 28]. Other ADs often prompt patients to indicate
preferences concerning specific life-prolonging treatments
[4, 17, 18]. It is known that patients may find it difficult
to complete such ADs [16, 19, 29]. In contrast, the pref-
erences sections of the MPF in our study contained two
sections that formulated preferences in a broader way, e.g.
‘goals of future care’ and ‘other preferences’. These sec-
tions shed light on the patients’ goals and intentions with
respect to medical treatment and care. Although less spe-
cific, it might be easier for patients to indicate their per-
spectives and preferences this way, which could result in
an increased completion of ADs. This highlights the need
for a conversation between the patient and their healthcare
professional in order to gain a better understanding of the
patient’s expressed preferences in an AD, and to suggest
and share thoughts on medical treatments that align to the
patient’s values.
It is important to be aware of some limitations of this study.
We included forms of patients who might be more open to
completing a form or who completed the form during the
conversation. This might have influenced the results of this
study. In addition, only one patient was a member of a minor-
ity ethnic group, this might limit the extent to which these
results can be applied to other populations. Additionally, al-
though translated carefully, some information or nuances may
have been lost in translation. However, by validating the re-
sults with native speaking researchers of each participating
country, we believe that we took sufficient measure to mitigate
this limitation.
In conclusion, this study provides the insight that being
independent, maintaining a normal life, having meaning-
ful relations and being free from pain are important topics
in ADs for patients with advanced cancer in Europe. A
more comprehensive AD, meaning an AD that includes
exploratory sections and preferences, provides healthcare
professional and relatives a better perspective of the most
important values of patients at the end of their life, and,
therefore, offers an opportunity to improve the guidance
of the healthcare professional. Having a conversation to
understand the reasoning behind indicated preferences re-
mains essential for relatives and healthcare professionals
to make decisions that are in line with the preferences of
the patient.
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